• Dr James GarnerMA, MBA, MBBS, BSC (HONS)

    Chief Executive Officer & Executive Director

    Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation.

    Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Kazia Therapeutics in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore.

  • Dr Peng LeongMBA, PHD

    Chief Business Officer

    Dr Leong has spent eighteen years in the pharmaceutical industry, beginning as a scientist, and followed by eight years in healthcare investment banking and private equity, and eight years in business development. Dr Leong started his career at Chiron Corporation, a pioneering biotechnology company based in California that was subsequently acquired by Novartis International AG (NYSE: NVS). While working in healthcare investment banking at CIBC World Markets and Piper Jaffray, he was involved in raising more than US$ 1.4 billion for over 20 biotechnology companies.

    In his various roles, including his most recent position at Merck Serono (FWB: MRK), Dr Leong has had a leadership role in the acquisition or sale of over US$ 1 billion in pharmaceutical product rights. He holds a PhD in Biochemistry from the University of Toronto, Canada and an MBA from the University of California, Berkeley.

  • Dr Gordon HirschMBA, MBBCh, FCP(SA), BSc Hons

    Chief Medical Officer

    Dr Hirsch is a scientist, specialist physician and pharmaceutical executive with more than 20 years’ experience in the pharmaceutical industry. He has held various scientific, medical and operational roles at country, regional and global levels with a range of responsibilities from development to commercialisation in companies including Eli Lilly, Pfizer, Sanofi and Takeda. He has held appointments in South Africa, Australia, France, Japan and the United States.

    He holds BSc Hons and MBBCh degrees from the University of the Witwatersrand, South Africa and an MBA from Henley Business School, UK. Dr Hirsch is also a Fellow of the South African College of Physicians.

  • Kate HillACA, GAICD, BSc (Hons)

    Company Secretary

    Kate has over 20 years’ experience as an audit partner with Deloitte Touche Tohmatsu, working with ASX listed and privately owned clients. She has worked extensively in regulated environments including assisting with Initial Public Offerings, capital raising and general compliance, as well as operating in an audit environment. She is also a Non-Executive Director of CountPlus Limited, an ASX listed company, and Chairs their Audit and Risk Committee. She is also a Non-Executive Director of a small not-for-profit organisation and a member of their Finance and Risk Committee. 

    Kate is a member of the Institute of Chartered Accountants in Australia and New Zealand, and a graduate of the Australian Institute of Company Directors.

  • Gabrielle HeatonBBUS (ACC), CPA

    Director of Finance and Administration

    Gabrielle Heaton has over 30 years of commercial experience in media, property services and healthcare for multinational, ASX listed and overseas companies.

    She has held a number of senior Finance positions including CFO, Quality Auditor and been responsible for Human Resources and IT.

    Gabrielle has a Bachelor of Business from the University of Technology and is a member of CPA Australia.